US Pharm. 2010;35(4):6.
Silver Spring, MD —The FDA has approved a name change for Kapidex (dexlansoprazole) to avoid confusion with two other medications. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant. Since Kapidex was approved in January 2009, there have been reports of dispensing errors due to confusion with the drugs Casodex (bicalutamide) and Kadian (morphine sulfate), which have very different uses. Kapidex is a proton pump inhibitor used to treat heartburn; Casodex, marketed by AstraZeneca, is used to treat advanced prostate cancer; and Kadian, distributed by Actavis Kadian LLC, is an opioid analgesic used to treat pain. There will be no changes made to Kapidex other than its name.
To comment on this article, contact email@example.com.